A-R-T- Advisors Has Lifted Its Novo (NVO) Holding; Catabasis Pharmaceuticals (CATB) Sellers Decreased By 62.47% Their Shorts

December 7, 2017 - By Michael Collier

A-R-T- Advisors Llc increased Novo (NVO) stake by 19.66% reported in 2017Q2 SEC filing. A-R-T- Advisors Llc acquired 8,100 shares as Novo (NVO)’s stock rose 15.20%. The A-R-T- Advisors Llc holds 49,300 shares with $2.11 million value, up from 41,200 last quarter. Novo now has $126.34B valuation. The stock increased 2.70% or $1.37 during the last trading session, reaching $52.07. About 2.15M shares traded or 16.30% up from the average. Novo Nordisk A/S (NYSE:NVO) has declined 23.93% since December 7, 2016 and is downtrending. It has underperformed by 40.63% the S&P500.

Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) had a decrease of 62.47% in short interest. CATB’s SI was 228,800 shares in December as released by FINRA. Its down 62.47% from 609,700 shares previously. With 367,900 avg volume, 1 days are for Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB)’s short sellers to cover CATB’s short positions. The SI to Catabasis Pharmaceuticals Incorporated’s float is 2.19%. The stock decreased 0.58% or $0.01 during the last trading session, reaching $1.71. About 121,305 shares traded. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has declined 73.74% since December 7, 2016 and is downtrending. It has underperformed by 90.44% the S&P500.

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 14 analyst reports since August 17, 2015 according to SRatingsIntel. Oppenheimer maintained it with “Buy” rating and $400 target in Monday, August 14 report. The firm has “Hold” rating by Cowen & Co given on Thursday, October 5. The firm earned “Buy” rating on Thursday, December 22 by H.C. Wainwright. Citigroup maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) on Thursday, October 5 with “Neutral” rating. As per Tuesday, March 22, the company rating was maintained by Citigroup. Citigroup maintained the shares of CATB in report on Thursday, June 9 with “Buy” rating. On Monday, November 20 the stock rating was upgraded by Citigroup to “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Monday, August 14. The stock has “Hold” rating by Cowen & Co on Thursday, August 10. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) earned “Outperform” rating by Wedbush on Wednesday, June 8.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $39.47 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com